Elanco Q1 revenue $1.205B; adjusted EPS $0.34; FY guidance updated with improved constant currency growth outlook

Elanco Animal Health Inc

2024-Q1 EPS reported $0.06 revenue$1,205,000,000

Q1 revenue $1.205B (-4% reported/CC); reported EPS $0.06, adjusted EPS $0.34; adjusted EBITDA $294M (-22%).
FY 2024 guidance: revenue $4.46-4.515B (2-3% CC growth), adjusted EBITDA $960M-$1B, adjusted EPS $0.88-$0.96.
Net leverage 6.1x; expects debt paydown $280-320M in 2024; aqua divestiture closing mid-2024 with proceeds $1.05-1.1B after tax.
Innovation revenue now expected $375-410M in 2024; three pipeline products (Bovaer, Zenrelia, Credelio Quattro) on track for H2 2024 approval.
Kexxtone sales paused due to EU CVMP review; expected ~$20M revenue and ~$18M adjusted EBITDA reduction vs Feb guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Elanco Animal Health Inc reported the first quarter of 2024 results: revenue $1,205 million, net income $32 million, EPS $0.06. Guidance reaffirmed.

Period: the first quarter of 2024
Revenue: $1,205 million
Net income: $32 million
EPS: $0.06
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Elanco Animal Health Reports First Quarter 2024 Results • First Quarter 2024 Financial Results ◦ Revenue of $1,205 million ◦ Reported Net income of $32 million, Adjusted Net income of $167 million ◦ Adjusted EBITDA of $294 million, or 24.4% of Revenue ◦ Reported EPS of $0.06, Adjusted EPS of $0.34

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Elanco Animal Health Inc filing history →

Source: SEC EDGAR

accession 0001739104-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.